Acute Effect of tDCS in Young Individuals

October 25, 2023 updated by: Taís Malysz, Federal University of Rio Grande do Sul

Acute Effect of tDCS on Motor Performance, Autonomic Control and Attentional and Executive Functions in Young Individuals

The aim of this study is to investigate the effect of transcranial electrical stimulation (tDCS) on motor performance, autonomic control and attentional and executive functions in young individuals.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Gait research in young and healthy individuals increases knowledge about the neuromuscular structures involved in this motor act and thus helps to develop or adapt therapeutic approaches that increase performance and/ or optimize the rehabilitation process for people with changes in gait control, and patients with neurological diseases. The aim of this study is to investigate the effect of transcranial electrical stimulation (tDCS) on motor performance, autonomic control and attentional and executive functions in young individuals. A total of 20 individuals (10 women and 10 men) aged 20-30 years will participate in this study. Each participant will visit the laboratory on three occasions, interspersed for one week, one visit for the initial evaluation (approximately 1 hour) and two visits for data collection, lasting approximately 1 hour and 40 minutes each. All participants will be randomly allocated in a double-blind and counterbalanced manner in the different experimental conditions. In one of the visits will be composing the intervention group (n=10; 20 min) and in another visit the Sham group (n=10). Outcomes related to motor performance (bilateral coordination, static and dynamic balance and functional mobility), heart rate variability and attentional and executive functions will be evaluated. To this end, the gait will be analyzed through the OpenCap motion analysis system from filming and after, the phase coordination index will be calculated for analysis of bilateral coordination; the stabilometry test will be used to assess the static balance of the participants, using a force platform where the participant remains standing on the platform to measure the center of pressure; functional mobility will be investigated from the 30-second sit-up test, aiming to analyze the dynamic balance and functional strength of the lower body, and the Timed up and Go Test used for balance analysis, gait and functional capacity. Heart rate variability will be recorded from the use of the Polar Vantage heart rate monitor (Finland), with the capacity of the R-R temporal record. The attentional and executive functions will be evaluated from the Stroop Test tool. These are three tasks with 24 items each, where the participant will be evaluated according to how quickly he performs the task and the amount of errors presented. The data will be described as mean. The normality of all data will be verified by the Shapiro-Wilk test. ANOVA with repeated measures of two factors will be used, followed by the Bonferroni post hoc test to compare the variables collected between the different conditions of brain stimulation (with and without application of tDCS) and between gait conditions. One-factor ANOVA will be used for brain stimulation conditions; data will be tabulated via Excel and statistical analyses will be performed in the SPSS software package for Windows version 24.0 (IBM, Chicago, USA). A significant value of p < 0.05 will be considered.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Brazil
    • RS
      • Porto Alegre, RS, Brazil, 90630150

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 20-30 years
  • participant of both sex

Exclusion criteria:

  • history of neurological or psychological diseases;
  • use of any medications that may affect balance control, such as sedative drugs;
  • presence of skeletal muscle injuries such as fracture, ligament injury, muscle tension or low back pain that restricts movement;
  • presence of any sign of involvement of the spinal cord;
  • visual or hearing impairment;
  • musculoskeletal deformities in the lower or upper extremities that may affect the participant's standing posture;
  • skin conditions (e.g., eczema and injuries) on the scalp
  • presence of metal inside the head (outside the mouth) such as splinters, surgical clips or fragments of solder or metal work;
  • implanted devices such as cardiac pacemaker, cochlear implant;
  • score less than 24 points in the Mini Mental State Examination (MMSE)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention
In the intervention group, the anodic stimulations will start after a ramp period of 30 s, followed by 20 min at 2 mili ampere and will end with a ramp of 30 s.
Device: cerebellar transcranial electrical stimulation
Cerebellar transcranial electrical stimulation - 20 mA - 20 min
Placebo Comparator: Placebo
In the simulated configuration, the ramp of 30 s will be immediately followed by the ramp of 30 s and without any current (Sham Group)
Device: cerebellar transcranial electrical stimulation
Cerebellar transcranial electrical stimulation - 20 mA - 20 min

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Effect of tDCS on motor performance
Time Frame: Through study completion, an average of 1 year
  • Bilateral coordination of different walking conditions will be assessed by percentage (%)
  • The static equilibrium will be evaluated by the average amplitude of displacement of the center of pressure in mean lateral and anteroposterior directions (cm)
Through study completion, an average of 1 year

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Effect of tDCS on functional mobility and dynamic balance
Time Frame: Through study completion, an average of 1 year
The 30-second sit and stand test - data expressed in number of repetitions The Time Up and Go Test (TUG) - data expressed in time(s)
Through study completion, an average of 1 year
Effect of variability of the heart rate
Time Frame: Through study completion, an average of 1 year
heart rate per min
Through study completion, an average of 1 year
Efect of tDCS on attentional and executive functions
Time Frame: Through study completion, an average of 1 year
time (s) to realize cognitives testes (Stroob test)
Through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Federal University of Rio Grande do Sul

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Taís Malysz, Federal University of Health Science of Porto Alegre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 16, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 25, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 31, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 31, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 25, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 71695023.3.0000.5347

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on cerebellar transcranial electrical stimulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings